State Board of Administration of Florida Retirement System Has $229.25 Million Stock Holdings in Abbott Laboratories $ABT

State Board of Administration of Florida Retirement System lifted its stake in Abbott Laboratories (NYSE:ABT) by 0.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,685,536 shares of the healthcare product maker’s stock after acquiring an additional 12,698 shares during the quarter. State Board of Administration of Florida Retirement System owned approximately 0.10% of Abbott Laboratories worth $229,250,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ABT. IMG Wealth Management Inc. raised its stake in shares of Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares in the last quarter. Elequin Capital LP acquired a new position in Abbott Laboratories during the first quarter worth $30,000. Anfield Capital Management LLC raised its position in Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after acquiring an additional 104 shares in the last quarter. Vision Financial Markets LLC bought a new stake in Abbott Laboratories during the first quarter worth $33,000. Finally, Accent Capital Management LLC acquired a new stake in Abbott Laboratories in the first quarter valued at $38,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ABT. Evercore ISI dropped their target price on shares of Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a report on Wednesday, October 15th. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Daiwa Capital Markets raised their price objective on Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a research report on Tuesday, October 21st. BTIG Research reiterated a “buy” rating and set a $145.00 target price on shares of Abbott Laboratories in a research note on Thursday, November 20th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $147.00 price objective on shares of Abbott Laboratories in a report on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $147.00.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $128.70 on Thursday. The stock has a 50 day simple moving average of $129.67 and a 200 day simple moving average of $131.08. The stock has a market cap of $223.80 billion, a P/E ratio of 16.13, a PEG ratio of 2.36 and a beta of 0.68. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The firm had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. During the same quarter last year, the business earned $1.21 EPS. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th were issued a $0.59 dividend. The ex-dividend date of this dividend was Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories’s payout ratio is currently 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.